Effect of thymosin α₁ on the phenotypic and functional maturation of dendritic cells from children with acute lymphoblastic leukemia.

Li X, Liu X, Zhao Y, Zhong R, Song A, Sun L

Molecular medicine reports30 Jul 2015Cited by 1 (Europe PMC)

PMID26239360DOI10.3892/mmr.2015.4153PepBankPUB-26239360

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In dendritic cells from children with ALL, Tα1-treated cells showed more apparent, characteristic dendritic morphology than control and antigen-only cells.
In plain wordsIn lab tests, thymosin alpha‑1 made immune cells from leukemia patient samples look more like mature dendritic cells than untreated cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseDendritic cell morphology
Study
humann = 10
Dendritic cells from PBMCs of children with acute lymphoblastic leukemia
Comparator
Antigen without Tα1 (AN) and control groups
Outcome group
Immune response · Immune and inflammation
Studied dose
100 ng/mlAs given in this study (human).
Source sentences
Summary
The DCs in the AT group exhibited more apparent, characteristic dendritic morphologies than the control and AN group DCs.
2 context sentences(design, population, supporting numbers)
Summary · context
The DCs were generated from the PBMC samples that were collected from the PB of 10 consecutive ALL children.
Summary · context
After 5 days of incubation, the AT group was administered with 100 ng/ml Tα1.
Report a problemFND-2623936001
02LabIn vitro (cells)Efficacy outcome
Tα1-treated dendritic cells had the lowest CD1a expression compared with antigen-only and control cells.
In plain wordsIn lab tests, thymosin alpha‑1 lowered CD1a on immune cells from leukemia patient samples compared with untreated cells.
Peptide
Thymosin alpha-1
Outcome
DecreaseCD1a expression on dendritic cells
Study
humann = 10
Dendritic cells from PBMCs of children with acute lymphoblastic leukemia
Comparator
Antigen without Tα1 (AN) and control groups
Outcome group
Immune response · Immune and inflammation
Studied dose
100 ng/mlAs given in this study (human).
Source sentences
Summary
Furthermore, the lowest expression level of CD1a, and the highest expression of CD83 and HLA‑DR were observed in the AT group when compared with the AN and control groups (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The DCs were generated from the PBMC samples that were collected from the PB of 10 consecutive ALL children.
Summary · context
After 5 days of incubation, the AT group was administered with 100 ng/ml Tα1.
Report a problemFND-2623936002
03LabIn vitro (cells)Efficacy outcome
Tα1-treated dendritic cells had the highest CD83 expression compared with antigen-only and control cells.
In plain wordsIn lab tests, thymosin alpha‑1 raised CD83 on immune cells from leukemia patient samples compared with untreated cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD83 expression on dendritic cells
Study
humann = 10
Dendritic cells from PBMCs of children with acute lymphoblastic leukemia
Comparator
Antigen without Tα1 (AN) and control groups
Outcome group
Immune response · Immune and inflammation
Studied dose
100 ng/mlAs given in this study (human).
Source sentences
Summary
Furthermore, the lowest expression level of CD1a, and the highest expression of CD83 and HLA‑DR were observed in the AT group when compared with the AN and control groups (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The DCs were generated from the PBMC samples that were collected from the PB of 10 consecutive ALL children.
Summary · context
After 5 days of incubation, the AT group was administered with 100 ng/ml Tα1.
Report a problemFND-2623936003
04LabIn vitro (cells)Efficacy outcome
Tα1-treated dendritic cells had the highest HLA-DR expression compared with antigen-only and control cells.
In plain wordsIn lab tests, thymosin alpha‑1 raised HLA-DR on immune cells from leukemia patient samples compared with untreated cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseHLA-DR expression on dendritic cells
Study
humann = 10
Dendritic cells from PBMCs of children with acute lymphoblastic leukemia
Comparator
Antigen without Tα1 (AN) and control groups
Outcome group
Immune response · Immune and inflammation
Studied dose
100 ng/mlAs given in this study (human).
Source sentences
Summary
Furthermore, the lowest expression level of CD1a, and the highest expression of CD83 and HLA‑DR were observed in the AT group when compared with the AN and control groups (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The DCs were generated from the PBMC samples that were collected from the PB of 10 consecutive ALL children.
Summary · context
After 5 days of incubation, the AT group was administered with 100 ng/ml Tα1.
Report a problemFND-2623936004
05LabIn vitro (cells)Efficacy outcome
The killing rate of cytotoxic T lymphocytes against wild-type leukemia cells was significantly higher in the Tα1 group than in the control and antigen-only groups.
In plain wordsIn lab tests, T cells primed with thymosin alpha‑1-treated cells killed leukemia cells at a higher rate than control T cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseCytotoxic T lymphocyte killing rate of leukemia cells
Study
humann = 10
Dendritic cells from PBMCs of children with acute lymphoblastic leukemia
Comparator
Antigen without Tα1 (AN) and control groups
Outcome group
Tumor growth · Cancer
Studied dose
100 ng/mlAs given in this study (human).
Source sentences
Summary
The lactate dehydrogenase release assay demonstrated that the killing rate of CTL in the AT group was significantly higher than that in the control and AN groups (P<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The DCs were generated from the PBMC samples that were collected from the PB of 10 consecutive ALL children.
Summary · context
After 5 days of incubation, the AT group was administered with 100 ng/ml Tα1.
Report a problemFND-2623936005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.